These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31375605)

  • 1. Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis.
    Chapman SR; Aladul MI; Fitzpatrick RW
    BMJ Open; 2019 Aug; 9(8):e026817. PubMed ID: 31375605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New mechanism to identify cost savings in English NHS prescribing: minimising 'price per unit', a cross-sectional study.
    Croker R; Walker AJ; Bacon S; Curtis HJ; French L; Goldacre B
    BMJ Open; 2018 Feb; 8(2):e019643. PubMed ID: 29439078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal prescribing behaviour associated with clinical software design features: a retrospective cohort study in English NHS primary care.
    MacKenna B; Curtis HJ; Walker AJ; Bacon S; Croker R; Goldacre B
    Br J Gen Pract; 2020 Sep; 70(698):e636-e643. PubMed ID: 32784218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy).
    Restelli U; Scolari F; Bonfanti P; Croce D; Rizzardini G
    BMC Infect Dis; 2015 Aug; 15():323. PubMed ID: 26259842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England.
    Cornford P; Halpin C; Sassmann J; Frankcom I; Braybrook S
    J Med Econ; 2023; 26(1):208-218. PubMed ID: 36749636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing competitive and sustainable Polish generic medicines market.
    Simoens S
    Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
    Tilson L; McGowan B; Ryan M; Barry M
    Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
    Zeng W
    BMC Health Serv Res; 2013 Oct; 13():390. PubMed ID: 24093493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
    Clarke PM; Fitzgerald EM
    Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting expenditure on medicines in the UK NHS.
    O'Neill P; Mestre-Ferrandiz J; Puig-Peiro R; Sussex J
    Pharmacoeconomics; 2013 Oct; 31(10):933-57. PubMed ID: 24037786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinician impact and financial cost to the NHS of litigation over pregabalin: a cohort study in English primary care.
    Croker R; Smyth D; Walker AJ; Goldacre B
    BMJ Open; 2018 Jun; 8(6):e022416. PubMed ID: 29880577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
    Lessing C; Ashton T; Davis P
    Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.